CHARACTERISTICS OF CHRONIC HEART FAILURE WITH ANEMIA
Keywords:
Chronic heart failure, functional class, quality of life, anemia, chronic kidney diseaseAbstract
In recent years, there are a number of scientific works and evidence confirming that anemia occupies one of the leading positions among the factors that worsen the quality of life of chronic heart failure (CHF) patients and have a negative impact on its duration. In developed countries, anemia is observed in 10-55% of patients with HF, and this indicator increases according to the severity of functional classes (FS) of the disease, and is 80% in IV FS of heart failure. Currently, anemia is considered an independent risk factor that negatively affects the course of the main disease, the outcome and the outcome of treatment. There are different theories about the pathogenesis and progression of anemia in patients with CKD, which requires a thorough study of this problem. When anemia is observed in this disease, its specific course, the death rate is twice as high as in patients without anemia, the problems of early diagnosis, effective treatment and prevention of this pathological process have yet to be solved.
References
Gadayev A.G., Turakulov R.I., Kurbanov A.K., Rakhimova M.E. Role of Hepcidin and ProInflammatory Cytokines in Chronic Heart Failure in Combination with Anemia. Central Asian Journal of Medicine 2019.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137– e161.
Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2015;52:501–511.
Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2015;161:822–831.e2.
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2014;368:1210–1219.
Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2016;13:387–392.
O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger
SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2016;113:986–994.
Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2014;107: 223–225.
Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014;89:88–96.
Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2015;112:1121–1127.
Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2015;26:2232–2237.
Anand IS, Rector T, Deswal A, Iverson E, Anderson S, Mann D, Cohn JN, Demets D. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J. 2016;27(suppl 1):485.
Montero D, Lundby C, Ruschitzka F, Flammer AJ. True anemia-red blood cell volume deficit-in heart failure: a systematic review. Circ Heart Fail. 2017.
Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2016;113:2713–2723.
Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2016;27:1440–1446.
Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2015;52:818–827.
